Prof. Dr. F. Lordick
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lordick, Florian
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, ZIIHERA®, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
10/25
05/26
NCT04460352 / 2020-000149-15: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
3
1020
Europe, Canada, RoW
Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)
Karolinska University Hospital, University of Leipzig, The Swedish Research Council
Esophageal Squamous Cell Carcinoma
12/26
12/31
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Active, not recruiting
2/3
429
Europe
FOLFIRI, Ramucirumab, Paclitaxel
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric or EGJ Cancer
12/25
12/25
VESTIGE, NCT03443856: Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Active, not recruiting
2
197
Europe, RoW
Nivolumab and Ipilimumab, chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Gastric and Esophagogastric Junction Adenocarcinoma
12/23
06/26
NCT06680622: Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

Recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
SAGA, NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Active, not recruiting
1/2
56
Europe
Sacituzumab govitecan, Trodelvy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences
Esophagogastric Adenocarcinoma
02/27
03/27
NCT04675138: Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care

Recruiting
N/A
1000
Europe, Japan, RoW
No intervention will be provided to the subject
National University Hospital, Singapore
Gastric Cancer, Esophageal Cancer, Esophagogastric Junction Cancer
12/24
12/24
SAPHIR, NCT04290806: Registry Platform Gastric/Esophageal Cancer

Recruiting
N/A
1900
Europe
Routine care as per site standard
iOMEDICO AG
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
12/28
12/28
Lordick, F
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lordick, Florian
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, ZIIHERA®, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
10/25
05/26
NCT04460352 / 2020-000149-15: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
3
1020
Europe, Canada, RoW
Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)
Karolinska University Hospital, University of Leipzig, The Swedish Research Council
Esophageal Squamous Cell Carcinoma
12/26
12/31
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Active, not recruiting
2/3
429
Europe
FOLFIRI, Ramucirumab, Paclitaxel
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric or EGJ Cancer
12/25
12/25
VESTIGE, NCT03443856: Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

Active, not recruiting
2
197
Europe, RoW
Nivolumab and Ipilimumab, chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Gastric and Esophagogastric Junction Adenocarcinoma
12/23
06/26
NCT06680622: Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

Recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
NeoART, NCT06731803: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Recruiting
1/2
36
Europe
Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Daiichi Sankyo
Esophagogastric Adenocarcinoma
12/27
12/27
SAGA, NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Active, not recruiting
1/2
56
Europe
Sacituzumab govitecan, Trodelvy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences
Esophagogastric Adenocarcinoma
02/27
03/27
NCT04675138: Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care

Recruiting
N/A
1000
Europe, Japan, RoW
No intervention will be provided to the subject
National University Hospital, Singapore
Gastric Cancer, Esophageal Cancer, Esophagogastric Junction Cancer
12/24
12/24
SAPHIR, NCT04290806: Registry Platform Gastric/Esophageal Cancer

Recruiting
N/A
1900
Europe
Routine care as per site standard
iOMEDICO AG
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
12/28
12/28
Lordick, F
No trials found

Download Options